Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
Date:5/2/2013

SAN FRANCISCO, May 2, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, June 10, 2013.

To access the conference call, follow these instructions:


Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)

Passcode: 36590300 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   Synthetic Biologics, Inc. ... on protecting the microbiome, as well as treating other ... appointed Chief Financial Officer, Treasurer and Secretary effective June ... who will be leaving the Company in May to ... Synthetic Biologics operational, financial and international biotech industry experience, ...
(Date:5/4/2015)... BOULDER, Colo., May 4, 2015  Array BioPharma ... for the third quarter of its fiscal year ... Chief Executive Officer of Array, noted, "With the close ... binimetinib and encorafenib, two innovative oncology products in ... each product in 2016. These transformative transactions have ...
(Date:5/4/2015)... , May 4, 2015 ... has granted an Orphan Drug Designation (ODD) for rimeporide, ... dystrophy (DMD). DMD is a rare, life-threatening disease affecting ... muscle loss. It is the most common and serious ... a selective sodium/proton exchanger type-1 inhibitor, originally developed by ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Peacock Alley ... our mothers. He said, “My mother was the most beautiful ... wrap her in lovely, feminine prints and textures ... Look no further than the Eloise Robe to get you ... with its cap sleeve and tapered waist. It is available ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... Singapore (PRWEB) May 03, 2015 ... enterprise collaboration across platforms and devices, today announced ... Association of Privacy Professionals (IAPP) Asia Privacy Forum, ... Hotel Orchard. Throughout the event, AvePoint will showcase ... hybrid, and cloud platforms. , Visit AvePoint for ...
(Date:5/3/2015)... Michigan (PRWEB) May 03, 2015 ... on their Facebook page. , Their Facebook ... the many services the Practice has, it’s multiple locations, ... , Women’s Excellence has a very strong social media ... Instagram and You Tube. , Women’s Excellence is ...
(Date:5/3/2015)... 2015 Leading international program provider, ... be awarding the 2015 Harris Wofford Global Service Fellowships. ... are the deserving recipients of the award named after ... Llewellyn Wofford. The two recipients were chosen for their ... health. , CFHI is one of seven organizations ...
Breaking Medicine News(10 mins):Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3
... LOS ANGELES, Sept. 1 Azteca America television network is proud ... Gavin Newsom on the Sept. 1 broadcast of "Issues: Caras ... , , As a self-styled "social liberal and ... healthcare and San Francisco is probably the highest profile city in ...
... 21 hours later with milder heart attacks, study shows , ... at hospital emergency rooms with chest pains can wait as ... electrocardiogram (EKG) shows evidence of a heart attack, a new ... key measures of heart damage and one-month death rates in ...
... , , National Veterans ... WASHINGTON, Sept. 1 More than 120 Veterans from across ... writing or visual arts contests are preparing to attend the National Veterans ... , "The Creative Arts Festival represents the top achievements ...
... ... orthopaedic surgeons Dr. James R. Andrews and Dr. Lonnie Paulos now beginning its second ... Gulf ... Sports Medicine is now providing free orthopaedic exams and assessments to high school ...
... , , , ... American Imaging Management(R) (AIM), an operating subsidiary of WellPoint, Inc. (NYSE: ... industry, today commended articles on diagnostic imaging that appear in the August 27, ... , The article "Exposure to Low-Dose Ionizing Radiation from Medical ...
... to detect the disease while it is still treatable ... say they have found small molecules in the blood ... have diagnostic implications in the future. , Levels of ... from pancreatic cancer, the fourth-leading cancer killer in the ...
Cached Medicine News:Health News:San Francisco Mayor Gavin Newsom Talks About Immigration and Drugs on Azteca America's 'Issues: Caras y Voces' 2Health News:Sometimes Angioplasty Can Wait 2Health News:VA Honors Veterans Who Are Artists, Performers 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 2Health News:Blood Test May Spot Pancreatic Cancer Early 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: